BET-IN-20

BET-IN-20 (compound 10) is an inhibitor of BRD4 BD1 (IC50=1.9 nM) with anticancer activity. BET-IN-20 can promote acute myeloid leukemia (AML) cell apoptosis and arrest the cell cycle in the G0/G1 phase. BET-IN-20 also inhibits c-Myc and CDK6 and enhances PARP cleavage[1].

Product Specifications

CAS Number

[1300735-76-5]

UNSPSC

12352005

Target

Apoptosis; Epigenetic Reader Domain

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bet-in-20.html

Solubility

10 mM in DMSO

Smiles

C[C@H](C1=CC=CC=C1)N2C(C3=C4)=C(N=C2C)C=NC3=CC(C5=C(C)ON=C5C)=C4OC

Molecular Formula

C25H24N4O2

Molecular Weight

412.48

References & Citations

[1]Yu S et al. Discovery of (R) -4- (8-methoxy-2-methyl-1- (1-phenylethy) -1H-imidazo [4, 5-c] quinnolin-7-yl) -3, 5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation[J]. European Journal of Medicinal Chemistry, 2023: 115924.